Risankizumab-Rzaa
Skyrizi
Interleukin-23 Antagonist
NADAC/unit
$9679.4921
No Shortage
Tier 1: 68.1%
PA Req: 368.4%
SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriat....
vs. brand Skyrizi: Generic saves up to -96695% per unit
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.